Results 81 to 90 of about 213,320 (307)
Drug Reformulation Regulatory Gaming in Pharmaceuticals: Enforcement & Innovation Implications [PDF]
, 2011 This article examines drug reformulation regulatory gaming as a vehicle for analyzing the way in which European courts and the Commission are currently approaching innovation issues in the pharmaceutical sector.
Battaglia, Lauren E.
core
Retailing under resale price maintenance: economies of scale and scope, and firm strategic response, in the inter-war British retail pharmacy sector [PDF]
, 2017 The article examines the impact of resale price maintenance (RPM) on market structure, productivity, and competitive advantage in British retail pharmacy.
Scott, Peter, Walker, James T.
core +1 more source
Is the Brazilian pharmaceutical policy ensuring population access to essential medicines?
Globalization and Health, 2012 Background To evaluate medicine prices, availability and affordability in Brazil, considering the differences across three types of medicines (originator brands, generics and similar medicines) and different types of facilities (private pharmacies ...
Bertoldi Andréa +4 more
doaj +1 more source
The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry [PDF]
The Janssen-Cilag proposal for a risk-sharing agreement regarding bortezomib received a welcome signal from NICE. The Office of Fair Trading report included risk-sharing agreements as an available tool for the National Health Service. Nonetheless, recent
Barros, Pedro Pita
core +1 more source
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
British Journal of Clinical Pharmacology, EarlyView.The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source
The relationship of drug reimbursement with the price and the quality of pharmaceutical innovations [PDF]
, 2005 This paper studies the strategic interaction between pharmaceutical firms' pricing decisions and government agencies' reimbursement decisions which discriminate between patients by giving reimbursement rights to patients for whom the drug is most ...
García-Alonso, M. D. C. +1 more
core
British Journal of Clinical Pharmacology, EarlyView.Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola +5 more
wiley +1 more source
POTENTIALS OF INTERACTIVE TEACHING TECHNIQUES TO TRAIN EXPERTS IN PHARMACY
Фармация и фармакология (Пятигорск), 2016 Various interactive teaching methods and techniques are extensively used in modern higher schools. Their implementation is considered to be one of the most significant and efficient ways to improve quality of pharmaceutical professional training ...
A. V. Krikova +4 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Aim Individual second‐generation antihistamines may possess differential sedative potential due to the variability in central histamine receptor H1 occupancy. This study aimed to evaluate whether the sedative potential of second‐generation antihistamines is associated with the risk of injury during Japan's pollen season. Methods We conducted a
Jumpei Taniguchi +3 more
wiley +1 more source
Frontiers in Public HealthIntroductionDrug accessibility is a core challenge facing global public health systems, with financing costs directly affecting drug prices through cost-plus pricing mechanisms.
Jingdong Huang, Xinyi Zhang
doaj +1 more source